TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Notice of FY results and Presentation via Investor Meet Company
Alderley Park, 20 May 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company's full year financial results for the year to 31 March 2024 will be released on Tuesday 28 May 2024.
The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.theracryf.com/investors.
Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via the Investor Meet Company platform at 3pm on Tuesday 28 May 2024.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 27 May 2024, 09:00 BST, or at any time during the live presentation. Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited.
Investors can sign up to Investor Meet Company HERE.
- Ends-
Enquiries
| TheraCryf plc Dr Helen Kuhlman, CBO | +44 (0)1625 315 090 |
| Cavendish Capital Markets (NOMAD and Broker) | +44 20 7220 0500 |
| Instinctif Partners Melanie Toyne-Sewell / Jack Kincade | +44 207 457 2020 |
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.
For further information, please visit: www.theracryf.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
